Form 4: Editas Medicine CFO Amy Parison Reports Stock Option Grant
SEC Form 4 Filing
Amy Parison, SVP and CFO of Editas Medicine, reports the grant of a stock option for 34,672 shares on April 8, 2025.
Summary
- Amy Parison, the SVP and Chief Financial Officer of Editas Medicine, Inc. (EDIT), filed a Form 4 on April 8, 2025.
- The filing reports the grant of a stock option to Parison on April 8, 2025, for 34,672 shares of Editas Medicine common stock.
- The exercise price of the stock option is $0.98.
- The option vests over four years, with 25% vesting on April 8, 2026, and the remaining 75% vesting in equal monthly installments through April 8, 2029.
- The stock option expires on April 7, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.
Positives
- The grant of stock options to the CFO aligns her interests with those of the shareholders.
- The vesting schedule incentivizes long-term performance and retention.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The vesting schedule is typical for such grants.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like CRISPR Therapeutics and Intellia Therapeutics also utilize stock options as part of their executive compensation plans.
- The vesting schedule of four years with a one-year cliff (25% vesting after one year) is a common structure.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CFO to drive long-term value.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 04/08/2025 | Date of stock option grant and Form 4 filing. |
| 04/08/2026 | Date when 25% of the stock options vest. |
| 04/08/2029 | Date when the remaining 75% of the stock options will be fully vested. |
| 04/07/2035 | Expiration date of the stock option. |
Keywords
Editas Medicine, Amy Parison, Stock Option, Form 4, Vesting, CFO, EDIT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.